Vicore and Endeavor’s therapies show promise in treating IPF
Both drugs have the potential to offer a disease-modifying approach to the lung disease
Read More
Tag: idiopathic pulmonary fibrosis
Vicore Pharma’s DTx to benefit pulmonary fibrosis patients
The nine-week DTxl CBT helps to address psychological symptom burdens in PF patients
Read More
AstraZeneca forges licensing agreement with Redx Pharma
AZ will pay $17m in early milestone payments for the UK biotech’s fibrotic asset
Read More
AZ to accelerate drug discovery with BenevolentAI partnership
The companies will create a team of two scientists that will work side-by-side to combine AstraZeneca’s genomics, chemistry and clinical data.
Read More
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
